NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

While Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders are probably generally happy, the stock hasn't ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...

Regeneron’s bid to join the market for BCMA ... Meanwhile, additional competition could be on the way in the form of AbbVie’s ABBV-383, another BCMAxCD3 bispecific that is in a registrational ...

Regeneron created Dupixent and markets it jointly ... and make sure their analysis is clear and in no way misleading or deceptive. To further protect the integrity of our editorial content ...

Wow. The issue, Regeneron has this fabulous eyecare franchise being challenged by an Amgen biosimilar. By the way, that’s a biotech version of just a generic drug but that’s all Wall Street ...

As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.

the Regeneron Science Talent Search is more than a passion project. Most adults couldn't understand Wen's research, which could end up being a stronger way to fight pancreatic cancer. "So ...